Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
Rhea-AI Summary
Lisata Therapeutics (Nasdaq: LSTA) will report third quarter 2025 financial results for the period ended September 30, 2025 on Thursday, November 6, 2025 after market close.
The company will host a conference call at 4:30 p.m. Eastern time the same day. Participants are encouraged to dial in 10 minutes early. Dial-in numbers: toll-free (800) 715-9871, toll/intl (646) 307-1963 with Conference ID 6375221. A live webcast will be available under the Investors & News section of Lisata’s website, with a replay posted two hours after the call and accessible for 12 months.
Positive
- None.
Negative
- None.
News Market Reaction 7 Alerts
On the day this news was published, LSTA gained 0.38%, reflecting a mild positive market reaction. Argus tracked a peak move of +17.1% during that session. Argus tracked a trough of -3.5% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $98K to the company's valuation, bringing the market cap to $26M at that time. Trading volume was elevated at 2.3x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
BASKING RIDGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. To join the live conference call, please refer to the dial-in information provided below.
Conference Call Dial-in information:
Participant Toll-Free dial: (800) 715-9871
Participant Toll/Int'l dial: (646) 307-1963
Conference ID: 6375221
To avoid delays, we encourage participants to dial into the conference call 10 minutes ahead of the scheduled start time.
A live webcast of the call will also be accessible under the Investors & News section of Lisata’s website and will be available for replay beginning two hours after the conclusion of the call for 12 months.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into the first quarter of 2027, encompassing anticipated data milestones from its ongoing clinical trials. For a comprehensive overview of certepetide's mechanism of action, please view our informative short film. For more information on the Company, please visit www.lisata.com.
Contact:
Investors:
Lisata Therapeutics
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
This press release was published by a CLEAR® Verified individual.
FAQ
When will Lisata Therapeutics (LSTA) release Q3 2025 results?
What time is Lisata Therapeutics (LSTA) Q3 2025 conference call and how do I join?
Where can I access the Lisata (LSTA) earnings webcast and replay?
Will Lisata (LSTA) provide a replay of the November 6, 2025 call and for how long?
Is there a recommended time to join Lisata (LSTA) conference call to avoid delays?
